Navigation Links
Study shows promise for new cancer-stopping therapy
Date:6/11/2009

Researchers at Nationwide Children's Hospital and Johns Hopkins University have discovered that delivering a small molecule that is highly expressed in normal tissues but lost in diseased cells can result in tumor suppression.

MicroRNAs (miRNA) are a class of small RNA molecules that are highly expressed in normal tissues and are critical in gene expression and in maintaining normal cell development and cell balance. Dysfunction of miRNAs has been linked to multiple human diseases including schizophrenia, autism and cancer.

"The pattern of expression of miRNAs has emerged as critically useful information for understanding cancer development and could be used to establish prognosis and treatment responses," said Janaiah Kota, PhD, a postdoctoral scientist from Nationwide Children's.

In a study reported in Cell (June 12, 2009), the team of researchers employed a novel strategy to treat an important form of cancer. Studies targeted hepatocellular (liver) cancer (HCC), the third leading cause of cancer-related deaths. HCC is commonly associated with underlying liver abnormalities, such as hepatitis B and C infections and cirrhosis. HCC is difficult to treat since it is often diagnosed at an advanced stage and because its biologic composition makes the tumor highly resistant to current drug therapies. However, the research reported in Cell suggests that miRNA gene delivery may be a clinically viable therapy when delivered by a recombinant adeno-associated virus (AAV).

HCC expresses a reduced number of miRNAs, including miR-26a. By combining miRNA technology developed at Johns Hopkins University with the gene delivery expertise of Nationwide Children's Hospital, scientists were able to successfully deliver AAV carrying miR-26a to a mouse with established HCC. This gene therapy strategy inhibited growth of cancer cells and led to tumor reduction and cell death, without causing toxic side effects to the remainder of the liver. This demonstrates for the first time that therapeutic delivery of a miRNA in an animal can result in tumor suppression, without the need for specifically targeting the cancer causing oncogene.

"We are eagerly looking forward to applying this methodology to other tumor types in the laboratory and potentially bringing this approach forward for clinical testing in patients," said Jerry Mendell, MD, director, Center for Gene Therapy in The Research Institute at Nationwide Children's Hospital and a faculty member of The Ohio State University College of Medicine. "While there remains significant work to be done both in identifying such miRNAs and optimizing their delivery, our findings highlight the therapeutic promise of this approach."

The findings of therapeutic miRNA gene replacement in HCC has potential for applicability to other types of cancers, as well. The delivery and restoration of miRNA expression via AAV mediated gene transfer of the miRNA may be beneficial to a large number of cancer subtypes.

"This concept of replacing microRNAs that are expressed in high levels in normal tissues but lost in diseases hasn't been explored before," said Josh Mendell, M.D., Ph.D., an associate professor in the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. "Our work raises the possibility of a more general therapeutic approach that is based on restoring microRNAs to diseased tissues."


'/>"/>

Contact: Mary Ellen Peacock
MaryEllen.Peacock@nationwidechildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Study finds segregation decreases access to surgical care for minorities
2. Kessler Foundation Research Center Study Provides Insight into One of the Most Challenging Symptoms Following a Traumatic Brain Injury
3. Kessler Foundation Research Center Study Provides Insight into One of the Most Challenging Symptoms Following a Traumatic Brain Injury
4. PAREXEL Enhances Study Start-Up and Recruitment Capabilities With Appointment of Dr. Lars-Olof Eriksson, Formerly With Merck
5. Want to Learn How to Testify? New Home Study Course by Practicing Physician Teaches Medical Malpractice Defendants and Physicians How to be Effective in Court
6. Morning Sickness Drug Gets Green Light in Study
7. DaVita Study Demonstrates Clinical Application of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
8. New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes
9. New Jefferson study may redefine how a chronic auto-immune disease is diagnosed
10. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
11. Published Study Shows VNUS ClosureFAST™ System Significantly Superior to Laser for Varicose Vein Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:1/16/2017)... ... ... well-aware of the following facts at present:, Flu and cold ... effect on keeping this particularly bad strain of the flu away , In ... , These facts are well-known among the team at Woodard! About halfway ...
(Date:1/16/2017)... Hills, CA (PRWEB) , ... January 16, 2017 ... ... a manuscript in the Aesthetic Surgery Journal , the official journal of ... he conducted on lower eyelid retraction surgery. The procedure is designed to correct ...
(Date:1/16/2017)... ... 16, 2017 , ... One thing common to all types of cancer is ... as well. The money spent screening for and treating cancer in the United States ... for cancer more than in any other country that has an advanced healthcare system, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar Medical, Inc. ... the medical device company, effective immediately. , “This is perfect timing for Kevin ... strong track record in medical device market development and revenue growth, particularly in ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , January 13, 2017 On ... Jones Industrial Average, and the S&P 500 edged lower ... ended Thursday,s trading session in bearish territories. Taking into ... Services equities this morning: Myriad Genetics Inc. (NASDAQ: ... ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017 /PRNewswire-USNewswire/ ... type 1 diabetes (T1D) research, is pleased to ... advocacy efforts, the Centers for Medicare & Medicaid ... devices approved by the FDA for use in ... a significant step toward making them eligible for ...
(Date:1/13/2017)... YORK , Jan. 12, 2017  Rosen Law ... filing of a class action lawsuit on behalf of ... ALXN ) from February 10, 2014 through November 9, ... recover damages for Alexion investors under the federal securities ... go to http://rosenlegal.com/cases-991.html or call Phillip ...
Breaking Medicine Technology: